Chonluten
Also known as: Lung bioregulator, EDG, T-34
Chonluten (also called Lung bioregulator or EDG) is a khavinson lung bioregulator. Chonluten is Glu-Asp-Gly, a synthetic tripeptide in the Khavinson series associated with bronchial epithelium and lung tissue. The proposed mechanism follows the series hypothesis: short peptides entering the nucleus and interacting with promoter regions to modulate transcription of tissue-relevant genes.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Not Approved
- Administration Route
- Subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Bronchial epithelium (proposed)
Vendor price snapshot
Price per mg is list price divided by vial size in milligrams when both are known from public vendor listings. Peptide Library does not sell peptides. Confirm live prices on the vendor site.
- Vendors listing this peptide
- 1
- Listed offers
- 1
- Price per mg range
- $2.50/mg
Research summary
Glu-Asp-Gly, a synthetic tripeptide in the Khavinson bioregulator series, sold as a bronchial and lung bioregulator. The proposed tissue-specific activity rests on older Russian-language cytogenetic work that has not been independently replicated, and no receptor or signalling pathway has been characterised. There is no modern randomised trial evidence for respiratory outcomes, and it is not FDA-approved.
Peptide Library's Chonluten profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Vendor research protocols only
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Chonluten is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Appearance | White lyophilized powder |
|---|---|
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Chonluten is Glu-Asp-Gly, a synthetic tripeptide in the Khavinson series associated with bronchial epithelium and lung tissue. The proposed mechanism follows the series hypothesis: short peptides entering the nucleus and interacting with promoter regions to modulate transcription of tissue-relevant genes. Reported findings concern normalisation of bronchial epithelial gene expression in older Russian-language cytogenetic work. There is no independent replication, no characterised receptor or signalling cascade, and no modern randomised controlled trial evidence for the claimed pulmonary effects.
Origin
Synthetic short peptide bioregulator.
Targets
Studies
- Napping and memory consolidation in early childhood: A systematic review and meta-analysis
- Using cognitive behavioral therapy-based chatbots to alleviate symptoms of insomnia, depression, and anxiety: A randomized controlled trial
- Non-Invasive Transcutaneous Afferent Patterned Stimulation Therapy Offers Action Tremor Relief in Parkinson's Disease
- Metabolomic Evaluation of the Central Metabolic Pathways of Mannosylerythritol Lipid Biosynthesis in Moesziomyces antarcticus T-34
- Steady beat and state anxiety
Regulatory & research status
Chonluten is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Potential Side Effects
Side Effects
- Not characterized
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Chonluten: frequently asked questions
What is Chonluten?
Glu-Asp-Gly, a synthetic tripeptide in the Khavinson bioregulator series, sold as a bronchial and lung bioregulator. The proposed tissue-specific activity rests on older Russian-language cytogenetic work that has not been independently replicated, and no receptor or signalling pathway has been characterised. There is no modern randomised trial evidence for respiratory outcomes, and it is not FDA-approved.
How does Chonluten work?
Chonluten is Glu-Asp-Gly, a synthetic tripeptide in the Khavinson series associated with bronchial epithelium and lung tissue. The proposed mechanism follows the series hypothesis: short peptides entering the nucleus and interacting with promoter regions to modulate transcription of tissue-relevant genes.
Is Chonluten FDA approved?
No. Chonluten is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Chonluten?
Compounds most often compared with Chonluten include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Napping and memory consolidation in early childhood: A systematic review and meta-analysis — Sleep Med, 2025External reference
- Using cognitive behavioral therapy-based chatbots to alleviate symptoms of insomnia, depression, and anxiety: A randomized controlled trial — Health Informatics J, 2025External reference
- Non-Invasive Transcutaneous Afferent Patterned Stimulation Therapy Offers Action Tremor Relief in Parkinson's Disease — Tremor Other Hyperkinet Mov (N Y), 2023External reference
- Metabolomic Evaluation of the Central Metabolic Pathways of Mannosylerythritol Lipid Biosynthesis in Moesziomyces antarcticus T-34 — J Oleo Sci, 2022External reference
- Steady beat and state anxiety — J Music Ther, 2011External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Chonluten profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Chonluten research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →